Logo
x

Search category

Subscribe Now

All Posts by Date

Zealand Pharma Reports Results from P-Ia Study of ZP8396 for Patients with Obesity and Diabetes

Zealand Pharma Reports Results from P-Ia Study of ZP8396 for Patients with Obesity and Diabetes

  • March 28, 2023
OncoVent, a Subsidiary of Hepalink and Orient EuroPharma Enters into a License and Distribution Agreement to Develop and Commercialize Oregovomab in Taiwan

OncoVent, a Subsidiary of Hepalink and Orient EuroPharma Enters into a License and Distribution Agreement to Develop and Commercia...

  • March 28, 2023
Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) Receives the MHLW’s Approval as the First HER2 Directed Therapy for HER2 Low Metastatic Breast Cancer

Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) Receives the MHLW’s Approval as the First HER2 Directed Therapy for HER2 Low Met...

  • March 28, 2023
GSK Reports P-III Trial (RUBY/ENGOT-EN6/GOG3031/NSGO) Results of Jemperli (dostarlimab) for Primary Advanced or Recurrent Endometrial Cancer

GSK Reports P-III Trial (RUBY/ENGOT-EN6/GOG3031/NSGO) Results of Jemperli (dostarlimab) for Primary Advanced or Recurrent Endometr...

  • March 28, 2023
Merck Reports P-III Trial (NRGGY018) Results of -Keytruda (pembrolizumab) as 1L Treatment for Advanced or Recurrent Endometrial Carcinoma

Merck Reports P-III Trial (NRGGY018) Results of -Keytruda (pembrolizumab) as 1L Treatment for Advanced or Recurrent Endometrial Ca...

  • March 28, 2023
Vertex Entered into a Non-Exclusive License Agreement with CRISPR Therapeutics to Advance Hypoimmune Cell Therapies for Type 1 Diabetes

Vertex Entered into a Non-Exclusive License Agreement with CRISPR Therapeutics to Advance Hypoimmune Cell Therapies for Type 1 Dia...

  • March 28, 2023
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.